ArticlePLoS biology2025
Most researchers would receive more recognition if assessed by article-level metrics than by journal-level metrics.
Article in PLoS biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- How contemporary academic structures constrain scientific creativity and hold back early-career researchers.Nature human behaviour · 2026Review
- Comparing the outputs of intramural and extramural grants funded by National Institutes of Health.eLife · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
During career advancement and funding allocation decisions in biomedicine, reviewers have traditionally depended on journal-level measures of scientific influence like the impact factor. Prestigious journals reject large quantities of papers, many of which may be meritorious. It is possible that this process could create a system whereby some influential articles are prospectively identified and recognized by journal brands, but most influential articles are overlooked. Here, we measure the degree to which journal prestige hierarchies capture or overlook influential science. We quantify the fraction of scientists' articles that would receive recognition because (a) they are published in journals above a chosen impact factor threshold, or (b) they are at least as well-cited as articles appearing in such journals. We find that the number of papers cited at least as well as those appearing in high-impact factor journals vastly exceeds the number of papers published in such venues. At the investigator level, this phenomenon extends across gender, racial, and career stage groupings of scientists. We also find that approximately half of researchers never publish in a venue with an impact factor above 15, which, under journal-level evaluation regimes, may exclude them from consideration for opportunities. Many of these researchers publish equally influential work; however, raising the possibility that the traditionally chosen journal-level measures that are routinely considered under decision-making norms, policy, or law, may recognize as little as 10%-20% of this influential work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.